Development of an IgG4-RD Responder Index

Published on Jan 1, 2012in International Journal of Rheumatology
· DOI :10.1155/2012/259408
Mollie N. Carruthers15
Estimated H-index: 15
(Partners HealthCare),
John H. Stone70
Estimated H-index: 70
(Partners HealthCare)
+ 1 AuthorsArezou Khosroshahi26
Estimated H-index: 26
IgG4-related disease (IgG4-RD) is a multiorgan inflammatory disease in which diverse organ manifestations are linked by common histopathological and immunohistochemical features. Prospective studies of IgG4-RD patients are required to clarify the natural history, long-term prognosis, and treatment approaches in this recently recognized condition. Patients with IgG4-RD have different organ manifestations and are followed by multiple specialties. Divergent approaches to the assessment of patients can complicate the interpretation of studies, emphasizing the critical need for validated outcome measures, particularly assessments of disease activity and response to treatment. We developed a prototype IgG4-RD Responder Index (IgG4-RD RI) based on the approach used in the development of the Birmingham Vasculitis Activity Score for Wegener's granulomatosis (BVAS/WG). The IgG4-RD RI was refined by members of the International IgG4-RD Symposium Organizing Committee in a paper case exercise. The revised instrument was applied retrospectively to fifteen IgG4-RD patients at our institution. Those scores were compared to physician's global assessment scale for the same visits. This paper describes the philosophy and goals of the IgG4-RD RI, the steps in the development of this instrument to date, and future plans for validation of this instrument as an outcome measure.
  • References (12)
  • Citations (115)
📖 Papers frequently viewed together
222 Citations
288 Citations
1,323 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1John H. Stone (Harvard University)H-Index: 70
#2Arezou Khosroshahi (Harvard University)H-Index: 26
Last. Suresh T. Chari (Mayo Clinic)H-Index: 74
view all 39 authors...
John H. Stone, Arezou Khosroshahi, Vikram Deshpande, John K. C. Chan, J. Godfrey Heathcote, Rob Aalberse, Atsushi Azumi, Donald B. Bloch, William R. Brugge, Mollie N. Carruthers, Wah Cheuk, Lynn Cornell, Carlos Fernandez-Del Castillo, Judith A. Ferry, David Forcione, Gunter Kloppel, Daniel L. Hamilos, Terumi Kamisawa, Satomi Kasashima, Shigeyuki Kawa, Mitsuhiro Kawano, Yasufumi Masaki, Kenji Notohara, Kazuichi Okazaki, Ji Kon Ryu, Takako Saeki, Dushyant Sahani, Yasuharu Sato, Thomas Smyrk, James...
377 CitationsSource
#1Arezou KhosroshahiH-Index: 26
Last. John H. StoneH-Index: 70
view all 6 authors...
AbstractPatients with IgG4-related disease (IgG4-RD) typically have elevated serum concentrations of IgG4 and share histopathologic features that are similar across affected organ(s). IgG4-RD patients frequently require prolonged treatment with glucocorticoids and are often unable to taper these med
304 CitationsSource
#1Patricia P. Katz (UCSF: University of California, San Francisco)H-Index: 63
16 CitationsSource
#1Taku TabataH-Index: 15
#2Terumi KamisawaH-Index: 56
Last. Tsuneo SasakiH-Index: 11
view all 8 authors...
Objective Autoimmune pancreatitis (AIP) and Mikulicz's disease have recently been recognized as pancreatic or salivary gland lesions of IgG4-related systemic disease. These are frequently associated with elevated serum IgG4 levels. This study aimed to clarify clinical implications of serial changes of elevated serum IgG4 levels in IgG4-related systemic diseases. Methods Serial changes of elevated serum IgG4 levels were examined in patients with IgG4-related systemic diseases. Patients Serial cha...
71 CitationsSource
Purpose of reviewTo summarize the existing knowledge of various clinical presentations of IgG4-related systemic disease (IgG4-RSD) and to review the evolving list of organs affected by IgG4-RSD.Recent findingsThe term IgG4-RSD encompasses a variety of clinical entities once regarded as being entirel
203 CitationsSource
Purpose of reviewIgG4-related systemic disease (IgG4-RSD) is a systemic fibroinflammatory condition that can affect any organ system. Prompt recognition and management of this disease process are necessary to prevent sclerosis and permanent organ damage. Here, we review the advances in treatment app
164 CitationsSource
An elevated serum titer of immunoglobulin G4 (IgG4), the least common (3% to 6%) of the 4 subclasses of IgG, is a surrogate marker for the recently characterized IgG4-related sclerosing disease. The syndrome affects predominantly middle-aged and elderly patients, with male predominance. The patients
296 CitationsSource
#1Arezou Khosroshahi (Harvard University)H-Index: 26
#2Donald B. Bloch (Harvard University)H-Index: 46
Last. John H. Stone (Harvard University)H-Index: 70
view all 4 authors...
Objective. Patients with IgG4-related systemic disease (IgG4-RSD) frequently show an incomplete response to treatment with glucocorticoids and traditional disease-modifying antirheumatic drugs (DMARDs). B lymphocyte depletion is a therapeutic strategy known to be effective for pemphigus vulgaris, an autoimmune condition mediated by IgG4 autoantibodies. This study was performed to assess the clinical and serologic responses to B lymphocyte depletion therapy with rituximab in patients with IgG4-RS...
341 CitationsSource
#1Richard A. Furie (North Shore-LIJ Health System)H-Index: 32
#2Michelle Petri (Johns Hopkins University)H-Index: 107
Last. William W. Freimuth (Human Genome Sciences)H-Index: 27
view all 12 authors...
Objective To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. Methods Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic ...
272 CitationsSource
#1Peter A. Merkel (BU: Boston University)H-Index: 67
#2David Cuthbertson (USF: University of South Florida)H-Index: 35
Last. John H. Stone (Harvard University)H-Index: 70
view all 12 authors...
Aim: Currently, several different instruments are used to measure disease activity and extent in clinical trials of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, leading to division among investigative groups and difficulty comparing study results. An exercise comparing six different vasculitis instruments was performed. Methods: A total of 10 experienced vasculitis investigators from 5 countries scored 20 cases in the literature of Wegener granulomatosis or microscopic ...
40 CitationsSource
Cited By115
#1Yanqiu Zheng (BCM: Baylor College of Medicine)
#2Khaled M. Elsayes (University of Texas MD Anderson Cancer Center)H-Index: 24
Last. Ayman H. Gaballah (MU: University of Missouri)H-Index: 2
view all 8 authors...
IgG4-related disease (IgG4-RD) is a systemic, autoimmune, fibroinflammatory disease that can cause multi-organ damage. Although there have been many trials and studies since its recognition in 2003, there is still much that is unknown. Furthermore, IgG4-RD can affect any organ in the body and often has many mimics and alternative diagnoses, which can make for a challenging workup. Imaging plays a substantial role in the diagnosis of IgG4-RD and is often the first occasion where IgG4-RD comes int...
#1Marta Casal Moura (Mayo Clinic)H-Index: 1
#2Ria Gripaldo (Emory University)
Last. Jay H. Ryu (Mayo Clinic)H-Index: 74
view all 4 authors...
Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibroinflammatory disorder that has been recognized to involve virtually any organ in the body and typically manifests mass-like lesions (tumefactive). Although initial reports of this disease (autoimmune pancreatitis [AIP]) were described in the Japanese population, it has since been reported worldwide. It is most commonly seen in adults of middle age or older, more often men than women. The pathogenesis of IgG4-RD is largely unknown, bu...
#1Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 14
#2Elena Rigamonti (UniSR: Vita-Salute San Raffaele University)H-Index: 8
Last. Shiv Pillai (Ragon Institute of MGH, MIT and Harvard)H-Index: 55
view all 19 authors...
Background IgG4-related disease (IgG4-RD) is a fibroinflammatory condition marked by rapid clinical improvement after selective depletion of B lymphocytes with rituximab. This feature suggests that B cells might participate in fibrogenesis and wound healing. Objective In the present work we aimed to demonstrate that B lymphocytes contribute directly to tissue fibrosis in patients with IgG4-RD. Methods Total circulating CD19+ B lymphocytes, naive B cells, memory B cells, or plasmablasts from pati...
#1Yanying Liu (PKU: Peking University)H-Index: 10
#2Qiaozhu Zeng (PKU: Peking University)
view all 15 authors...
OBJECTIVES: Patients with IgG4-related disease (IgG4-RD) typically respond well to initial glucocorticoid therapy, but always relapse with tapered or maintenance dosage of steroid. We aimed to identify the risk factors for relapse of IgG4-RD and explore the impact of active intervention on the serologically unstable condition. METHODS: We performed a retrospective study of 277 IgG4-RD patients at Peking University People's Hospital from February 2012 through February 2019. They were all followed...
1 CitationsSource
#1Hayato Yabe (Sapporo Medical University)H-Index: 1
#2Ryuta Kamekura (Sapporo Medical University)H-Index: 17
Last. Hiroki Takahashi (Sapporo Medical University)H-Index: 45
view all 12 authors...
AbstractObjectives: The aim of this study was to determine pathological features of T peripheral helper (Tph)-like (PD-1+CXCR5−CD4+ T) cells in IgG4-related disease (IgG4-RD).Methods: Tph-like cell...
#1Yiwen Wang (Chinese PLA General Hospital)H-Index: 2
#2Zheng Zhao (Chinese PLA General Hospital)H-Index: 2
Last. Xiuru Wang (Chinese PLA General Hospital)H-Index: 2
view all 18 authors...
ABSTRACT Objectives : To evaluate the efficacy and safety of leflunomide (LEF) and glucocorticoids (GCs) combination therapy compared with GCs monotherapy in preventing relapse of IgG4-related disease (IgG4-RD). Methods : A 12-month, randomized, open-label, controlled trial was conducted at a large academic medical center ( NCT02703194). Enrolled patients with active IgG4-RD were randomly allocated to the GCs + LEF (20 mg/day) combination therapy or GCs monotherapy group. All ...
2 CitationsSource
The field of idiopathic orbital inflammation has come into motion: Ever since the first description of IgG4-associated disease about 10 years ago, the group of idiopathic lesions has shrunk by about half. The differential diagnosis has become much more demanding because the clinical and imaging overlap is considerable. This article presents a review of idiopathic orbital inflammation, IgG4-associated disease, and orbital lymphoid hyperplasia. All three conditions can have significant - and quite...
#1Yanying Liu (PKU: Peking University)H-Index: 10
#2Yuxin Zhang (PKU: Peking University)
Last. Zhanguo Li (PKU: Peking University)H-Index: 26
view all 11 authors...
Objective To evaluate the therapeutic efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease (IgG4-RD).
#1Zhi-Ying Li (PKU: Peking University)H-Index: 4
#2Xu Wang (PKU: Peking University)
Last. Ming-hui Zhao (PKU: Peking University)H-Index: 7
view all 8 authors...
Abstract Background We investigated the characteristics of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (ANCA-GN) and immunoglobulin G4 (IgG4)-related kidney disease (IgG4-RKD) overlap syndrome. Methods Thi is a 2-center study with 19 patients. Results Fifteen patients were classified as microscopic polyangiitis (MPA). The initial serum creatinine levels were 320.9±191.4 μmol/l and the BVAS was 19.7±7.4 at diagnosis. Hematuria was absent or slight in 13 (68.4%) cases....
#1J. LiH-Index: 2
Last. Yan ZhaoH-Index: 36
view all 13 authors...
Background To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved.